RESUMO
Ovary cancer treatment often presents clinical promlems due to frequent occurence of late diagnostics (III-IV stages), severe treatment complications in patients with ascitis and tumor intoxication. Reamberin can be used as supportive therapy aimed at decrease of intoxication, which is one of the main hindrances for antitumor therapy. In the current study reamberin was used in 89 stage III-IV (FIGO) ovary cancer patients with ascitis, age 42 to 79, CP or CAP chemotherapy recipients after prior cytoreductive surgery. The occurrence of hematological complications (grade 1-2 anemia and neutropenia) and cardiac dysfunctions in the study group was much lower, than in the control group. This difference is statistically valid (p < 0.01 and p < 0.05). The patients receiving reamberin prior to chemotherapy or during chemotherapy rarely (in 3.7% of cases) displayed raised creatinine values. In the control group grade 1-3 renal impairment was observed in 41.4% cases, in 12 cases the therapy had to be ceased. This difference between the groups is statistically valid (p < 0.001). Patients receiving reamberin displayed more rapid rate of CA-125 tumor marker serum concentration decrease. Therefore, reamberin is an effective drug for prevention of chemotherapy side effects and alleviation of intoxication allowing the more rigid chemotherapy schedule without an increase in toxicity.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Meglumina/análogos & derivados , Neoplasias Ovarianas/tratamento farmacológico , Neoplasias Ovarianas/patologia , Prevenção Primária/métodos , Substâncias Protetoras/uso terapêutico , Succinatos/uso terapêutico , Adulto , Idoso , Cistadenocarcinoma Seroso/tratamento farmacológico , Cistadenocarcinoma Seroso/patologia , Feminino , Humanos , Meglumina/uso terapêutico , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Indução de RemissãoRESUMO
Owing to its anatomo-topographic features, ovarian carcinoma starts to disseminate at early stages. Views on surgical treatment are divided between radical removal of all metastatic tissues, and operation "within reasonable limits of safety". Volume of surgery is discussed on the basis of the available literature and our own data with due consideration of patterns of tumor dissemination and recurrence and a complex of intraperitoneal factors. Potential of nanotechnologies and, in particular, photodynamic therapy of relapsing canceromatosis of the peritoneum is discussed.